Vaxart Stock News

Vaxart is the oral vaccine developer with COVID, RSV, HPV, influenza and Norovirus candidates in its pipeline.

Vaxart Inc. (NASDAQ:VXRT)s traded shares stood at 2.12 million during the last session, with the companys beta value hitting 0.23. At the close of trading, the stocks price was $6.56, to imply an increase of 3.31% or $0.21 in intraday trading. The VXRT shares 52-week high remains $24.90, putting it -279.57% down since that peak Vaxart Inc. (NASDAQ: VXRT): Can A Stock Be 14.89% Higher Year-To-Date And Still Be A Loser? Read More »

The initial data on omicron suggests that the pandemic has entered a new, less deadly phase.

The initial data on omicron suggests that the pandemic has entered a new, less deadly phase.

Analysts predict that Vaxart, Inc. (NASDAQ:VXRT) will post earnings per share of ($0.16) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Vaxarts earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.18). Vaxart reported earnings of ($0.13) per share during the []

Wall Street brokerages forecast that Vaxart, Inc. (NASDAQ:VXRT) will announce $860,000.00 in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Vaxarts earnings, with the highest sales estimate coming in at $2.70 million and the lowest estimate coming in at $200,000.00. Vaxart reported sales of $360,000.00 during the same quarter last [] The post Zacks: Analysts Expect Vaxart, Inc. (NASDAQ:VXRT) Will Announce Quarterly Sales of $860,000.00 appeared first on ETF Daily News .

Vaxart, Inc. (NASDAQ:VXRT)s stock price dropped 6.3% on Thursday following insider selling activity. The stock traded as low as $6.57 and last traded at $6.59. Approximately 56,140 shares traded hands during trading, a decline of 100% from the average daily volume of 11,598,938 shares. The stock had previously closed at $7.03. Specifically, SVP Margaret Echerd []

Despite a new factory acquisition, VXRT stock is down 9% on the day as 'Mad Money' host Jim Cramer warns investors about Vaxart. The post VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Ju

Purchase expected to give Vaxart greater control over manufacturing schedules Purchase expected to give Vaxart greater control over manufacturing schedules

Vaxart Inc. (NASDAQ: VXRT) shares were trading higher Monday. A company executive will present an overview of the company’s COVID-19 oral vaccine candidate at the World Vaccine & Immunotherapy Cong

Vaxart Inc. (NASDAQ: VXRT ) shares were trading higher Monday. A company executive will present an overview of the companys COVID-19 oral vaccine candidate at the World Vaccine & Immunotherapy Congress on Tuesday, Nov. 30. The stock looks to be breaking out of resistance Monday. Vaxart was up 0.94% at $7.55 Monday afternoon. See Related: Why Vaxart Stock Is About Ready To See A Breakout Vaxart Daily Chart Analysis Shares look to have broken out of what technical traders call a pennant pattern and are looking to test old resistance as support. The price has been getting squeezed between narrowing highs and Full story available on Benzinga.com

Vaxart, Inc. (VXRT) with the stream of 5.06% also noticed, India Fisker Inc. (FSR) encountered a rapid change of -2.89% in the last hour of trading session. Vaxart, Inc. (NASDAQ:VXRT) The post Impulsive Stock: Vaxart, Inc. (NASDAQ:VXRT), Fisker Inc. (NYSE:FSR) appeared first on Stocks Equity .

As vaccine makers pursue the next generation of COVID-19 vaccines, some are working to develop products that wouldn''t require a shot. Why it matters: Delivering a vaccine through a pill or a nasal spray could make them much easier to administer, especially in places where distribution is challenging or even for people who just don''t like needles. Driving the news: San Francisco-based biotech Vaxart is working on a COVID vaccine that would be delivered in an oral tablet. India''s Bharat Biotech advanced its nasal COVID-19 vaccine candidate into a phase 2 clinical trial earlier this fall . What they''re saying: Vaxart founder and chief scientific officer Sean Tucker told Axios he started the company because he found it difficult to get his flu shot every year. "I thought ''Hey, if someone mailed me a tablet in the mail every year, I would take that vaccine all the time,''" Tucker said. State of play: Tucker will present details of the oral vaccine program at the World Vaccine & Immunotherapy Congress West Coast 2021 next week.

Innate Pharma (NASDAQ:IPHA) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends. Valuation and Earnings This table compares Innate Pharma and Vaxarts top-line revenue, earnings per share (EPS) []